

OM nucleic - nucleic search, using sw model

Run on: June 1, 2003, 14:56:34 ; Search time 466.436 Seconds
(without alignments)
10776.324 Million cell updates/sec

Title: US-09-625-573-1
Perfect score: 2232
Sequence: 1 GGATTGAACAGGACGCAATT.....TATAACTATGTTGATATAAAG 2232

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues
Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_101002.*
1: /SID22/cgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SID22/cgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SID22/cgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SID22/cgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SID22/cgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SID22/cgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SID22/cgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SID22/cgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SID22/cgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SID22/cgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SID22/cgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SID22/cgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SID22/cgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SID22/cgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SID22/cgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SID22/cgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SID22/cgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SID22/cgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SID22/cgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SID22/cgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SID22/cgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SID22/cgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SID22/cgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SID22/cgdata/geneseq/geneseq-emb1/NA2002.DAT.*

SUMMARIES				Description	
Result No.	Score	Query Match	Length DB ID	Description	
1	2232	100.0	2232 16	AAQ96297	Human monocyte che
2	1250.8	56.0	143068 21	AAF21105	Human low adenosin
3	1250.8	56.0	143068 21	AAF21272	Human low adenosin
4	1250.8	56.0	143068 21	AA34983	Human adenosine re
5	1250.8	56.0	143068 21	AA35150	Human adenosine re
6	1250.8	56.0	143068 21	ABL68124	Ovary cancer relat
7	1250.8	56.0	149412 21	AA35151	Human adenosine re
8	1250.8	56.0	152740 21	AAF21273	Human low adenosin
9	980	43.9	1979 16	AAQ96298	Human monocyte che

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

ALIGNMENTS

RESULT 1
AAQ96297
ID AAQ96297 standard; cDNA; 2232 BP.
XX
AC AAQ96297;
XX
XX 29-DEC-1995 (first entry)
DT Human monocyte chemoattractant protein-1 receptor MCP-1RA.
XX Monocyte chemoattractant protein-1 receptor; MCR-1R; chemokine; ss.
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH 40..1161
FT /*tag= a
FT
XX
XX WO9519436-A.
XX
XX 20-JUL-1995.
XX
XX 11-JAN-1995; 95WO-US00476.
XX
XX 13-JAN-1994; 94US-0182962.
XX (REGC) UNIV CALIFORNIA.
XX Charo I, Coughlin S;
XX WPI; 1995-263866/34.
XX P-PSDB; AAR9165.
DR

XX

PT DNA encoding monocyte chemo-attractant protein-1 receptor - used partic.
 PT for identifying antagonists and for treating diseases characterised by
 XX monocytic infiltrates

PS Disclosure; Fig 1; 84pp; English.

XX To identify and clone new members of the chemokine receptor gene
 CC family, degenerate oligo primers were designed correspond. to the
 CC conserved sequences R79167 in the second and R79168 in the third
 CC transmembrane domains of the MIP-1alpha/RANTES receptor, the IL-8
 CC receptors and the HUMSTERS orphan receptor (GenBank Accession #M99293.
 CC The degenerate oligo incorporating EcoRI and XhoI sites at their 5',
 CC ends are Q96299 and Q96300. Amplification of cDNA derived from MM6
 CC cells with the primers yielded a number of PCR products. One cDNA
 CC appeared to encode a novel protein. To obtain a full-length version
 CC of this clone, a MM6 cDNA library was constructed in pSROG and probed
 CC with the PCR product. A 2.1 kb cDNA clone was obtained. Analysis of
 CC additional clones in the MM6 cDNA library revealed a second
 CC sequence that was identical to the 2.1 kb cDNA sequence first obtained.
 CC from the 5' UTR through the putative seventh transmembrane domain
 CC but contained a different cytoplasmic tail. The second sequence
 CC appears to represent alternative splicing of the carboxyl-terminal
 CC tail of the MCP-1R protein. The two sequences are denoted MCP-1RA
 CC and MCP-1RB (see Q96297/R79165 & Q96298/R79166). Active mature
 CC MCP-1RA has a predicted mol. wt. of about 42,000 daltons. MCP-1RB
 CC has a mol. wt. of about 41,000 daltons.

XX Sequence 2232 BP; 602 A; 464 C; 508 G; 658 T; 0 other;

Query Match 100.0%; Score 2232; DB 16; Length 2232;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2232; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGATTGAACAGGAGCGCATTTCCCGAGTACATCCCAACATCGTGCCACATCTCGTTCT 60
 DB 1 GGATTGAACAGGAGCGCATTTCCCGAGTACATCCCAACATCGTGCCACATCTCGTTCT 60
 QY 61 CGGTTTATCAGAAATACCAACAGAGCGGTGAAGAGTCAACACCTTTTGGATTATGAT 120
 DB 61 CGGTTTATCAGAAATACCAACAGAGCGGTGAAGAGTCAACACCTTTTGGATTATGAT 120
 QY 121 TACGGTCTCCCTGTCATAAATTTGACGTGAAGCAAAATTTGGGCGCCCACTCTCGCTCG 180
 DB 121 TACGGTCTCCCTGTCATAAATTTGACGTGAAGCAAAATTTGGGCGCCCACTCTCGCTCG 180
 QY 181 CTCTACTCGCTGGTTCATCTTTGGTTTGTGGGCAACATCGTGGTCTCTCATCTTA 240
 DB 181 CTCTACTCGCTGGTTCATCTTTGGTTTGTGGGCAACATCGTGGTCTCTCATCTTA 240
 QY 241 ATAACTGCAAAAGCTGAAGTGTGACTGACATTTACCTGCTCAACCTGGCCATCTCT 300
 DB 241 ATAACTGCAAAAGCTGAAGTGTGACTGACATTTACCTGCTCAACCTGGCCATCTCT 300
 QY 301 GATCTGCTTTTCTTATTACTCTCCCAATTTGGGCTCACTCTGCTGCAAAATGAGTGGGTC 360
 DB 301 GATCTGCTTTTCTTATTACTCTCCCAATTTGGGCTCACTCTGCTGCAAAATGAGTGGGTC 360
 QY 361 TTTGGGAATGCAATGTCAAAATTTACAGAGGCTGTATCATACATCGGTTATTTGGCCGA 420
 DB 361 TTTGGGAATGCAATGTCAAAATTTACAGAGGCTGTATCATACATCGGTTATTTGGCCGA 420
 QY 421 ATCTTCTTCATATCCCTCCATGACATATGATACCTTGGCTATTTGCTCATCTGCTGTTT 480
 DB 421 ATCTTCTTCATATCCCTCCATGACATATGATACCTTGGCTATTTGCTCATCTGCTGTTT 480
 QY 481 GCTTTAAAGCCAGGAGGTCACCTTTGGGCTGTGATCAAGTGTGATCACTGGTTGGTG 540
 DB 481 GCTTTAAAGCCAGGAGGTCACCTTTGGGCTGTGATCAAGTGTGATCACTGGTTGGTG 540
 QY 541 GCTGTGTTTCTTCTGTCCAGGAATCATCTTTACTTAAATGCCAGAAAGAGATCTGTT 600
 DB 541 GCTGTGTTTCTTCTGTCCAGGAATCATCTTTACTTAAATGCCAGAAAGAGATCTGTT 600

QY 601 TATCTCTGTGGCCCTTATTTTCCAGGAGATGAATAATTTCCACACAATAATGAGGAAC 660
 DB 601 TATCTCTGTGGCCCTTATTTTCCAGGAGATGAATAATTTCCACACAATAATGAGGAAC 660
 QY 661 ATTTTGGGGCTGCTCCTCGCTGCCTCATCATGTCTATCTGCTACTCGGGAATCCTGAAA 720
 DB 661 ATTTTGGGGCTGCTCCTCGCTGCCTCATCATGTCTATCTGCTACTCGGGAATCCTGAAA 720
 QY 721 ACCCTGCTTCGGTGTGCGAAGAGAGGATAGGCGATAGGCGAGTGCATCTTCCACACC 780
 DB 721 ACCCTGCTTCGGTGTGCGAAGAGAGGATAGGCGATAGGCGAGTGCATCTTCCACACC 780
 QY 781 ATCATGATGTTTACTTCTTCTTGGACTCCCTATAACATTTGCTATCTTCTCTGAAACACC 840
 DB 781 ATCATGATGTTTACTTCTTCTTGGACTCCCTATAACATTTGCTATCTTCTCTGAAACACC 840
 QY 841 TTCCAGGAATTTCTCGGCTGAGTAACCTGTGAAGCACCAGTCACTGGACCAAGCCACG 900
 DB 841 TTCCAGGAATTTCTCGGCTGAGTAACCTGTGAAGCACCAGTCACTGGACCAAGCCACG 900
 QY 901 CAGGTGACAGAGACTCTTTGGGATGACTCACTGCTGCATCAATCCCATCATCTATGCTTTC 960
 DB 901 CAGGTGACAGAGACTCTTTGGGATGACTCACTGCTGCATCAATCCCATCATCTATGCTTTC 960
 QY 961 GTTGGGGAAGATTTCAGAAAGCCTTTTTCACATAGCTCTTGGCTGTAGGATTGGCCCACTC 1020
 DB 961 GTTGGGGAAGATTTCAGAAAGCCTTTTTCACATAGCTCTTGGCTGTAGGATTGGCCCACTC 1020
 QY 1021 CAAAACACAGTGTGTGGAGTCCAGGAGTGGAGACAGGAAAGAAATGTGAAAGTGACTACA 1080
 DB 1021 CAAAACACAGTGTGTGGAGTCCAGGAGTGGAGACAGGAAAGAAATGTGAAAGTGACTACA 1080
 QY 1081 CAAGGACTCTCTGATGCTGTGGAAAGAGTCAATTTGGCAGAGCCCTGGAAGCCAGT 1140
 DB 1081 CAAGGACTCTCTGATGCTGTGGAAAGAGTCAATTTGGCAGAGCCCTGGAAGCCAGT 1140
 QY 1141 CTTGAGCAAAAGAGGAGCCTTAGAGACAGAAATGACAGATCTCTGCTTTGGAAATCACA 1200
 DB 1141 CTTGAGCAAAAGAGGAGCCTTAGAGACAGAAATGACAGATCTCTGCTTTGGAAATCACA 1200
 QY 1201 CGTCTGCTTCACAGATGTGTGATTCACAGTGTGAATCTTGGTGTCTACGTATACCGCA 1260
 DB 1201 CGTCTGCTTCACAGATGTGTGATTCACAGTGTGAATCTTGGTGTCTACGTATACCGCA 1260
 QY 1261 GGAAGGCTGAGAGGAGAGACTCCAGCTGGTGGTGGAAACAGATATTTTCCAACTACTC 1320
 DB 1261 GGAAGGCTGAGAGGAGAGACTCCAGCTGGTGGTGGAAACAGATATTTTCCAACTACTC 1320
 QY 1321 TCAGTTCCTCATTTTGTGAATACAGGATAGAGTTCAGACTTTTTTAAATAGTAAAT 1380
 DB 1321 TCAGTTCCTCATTTTGTGAATACAGGATAGAGTTCAGACTTTTTTAAATAGTAAAT 1380
 QY 1381 AAAATTAAGCTCAAACTGCACTTGAATGTGGTAAAGAGTAGTTTGTGAGTTGCTPAT 1440
 DB 1381 AAAATTAAGCTCAAACTGCACTTGAATGTGGTAAAGAGTAGTTTGTGAGTTGCTPAT 1440
 QY 1441 CATGTCAAAAGCTGAAAATGCTGTATTACTCACAGAGATAATTTAGCTTTTCAGCTTAAGA 1500
 DB 1441 CATGTCAAAAGCTGAAAATGCTGTATTAGTCAACAGAGATAATTTAGCTTTTCAGCTTAAGA 1500
 QY 1501 ATTTTCAGCAGGTGGTATGTTTGGGAGACTGCTGAGTCAACCCCAATAGTTTGTGATGGC 1560
 DB 1501 ATTTTCAGCAGGTGGTATGTTTGGGAGACTGCTGAGTCAACCCCAATAGTTTGTGATGGC 1560
 QY 1561 AGGAGTTGGAAGTGTGTGATCTGTGGGACATGCTGAGTCAACCCCAATAGTTTGTGATGGC 1620
 DB 1561 AGGAGTTGGAAGTGTGTGATCTGTGGGACATGCTGAGTCAACCCCAATAGTTTGTGATGGC 1620
 QY 1621 ATGATGCTGTTTGAATACAGATATACGCTCCATCGTGTGATCTCAGCTGGATCTCCATT 1680
 DB 1621 ATGATGCTGTTTGAATACAGATATACGCTCCATCGTGTGATCTCAGCTGGATCTCCATT 1680

Db	48313	GGTCCAGGAGTGTAGACACGAGAAAGAAATGTGAAGTGAATCTACACAGGACTCCTCGATCGT	48372
QY	1099	CGTGGAAAAGGAAAGTCAATTGGCAGAGCCCTGAAGCCAGTCTTTCAGSACAAAGAAGGA	1158
Db	48373	CGTGGAAAAGGAAAGTCAATTGGCAGAGCCCTGAAGCCAGTCTTTCAGSACAAAGAAGGA	48432
QY	1159	GCCTAGAGACAGAAATGACAGATCTCTGGTTTGGAAATCACACGTCGGCTTCACAGATG	1218
Db	48433	GCCTAGAGACAGAAATGACAGATCTCTGGTTTGGAAATCACACGTCGGCTTCACAGATG	48492
QY	1219	TGTGATTCACAGTGTGAATCTCTGGTGTCTACGTTTACAGGCAGGAAGGCTGAGAGGAG	1278
Db	48493	TGTGATTCACAGTGTGAATCTCTGGTGTCTACGTTTACAGGCAGGAAGGCTGAGAGGAG	48552
QY	1279	AGACTCCAGCTGGGTTGGAAAAACAGTATTTTCCAAACTACCTTCCAGTTCCCTCATTTTG	1338
Db	48553	AGACTCCAGCTGGGTTGGAAAAACAGTATTTTCCAAACTACCTTCCAGTTCCCTCATTTTG	48612
QY	1339	AATACAGGCATAGAGTTCAGACTTTTTTAAATAGTAAAAATAAAATTAAGCTGAAAAAC	1398
Db	48613	AATACAGGCATAGAGTTCAGACTTTTTTAAATAGTAAAAATAAAATTAAGCTGAAAAAC	48672
QY	1399	TGCAACTGTAAATGTGGTAAAGAGTTAGTTTGGTTGCTTATCATGTCAAAAGCTGAAAAAT	1458
Db	48673	TGCAACTGTAAATGTGGTAAAGAGTTAGTTTGGTTGCTTATCATGTCAAAAGCTGAAAAAT	48732
QY	1459	GCTGTATTAGTTCACAGAGATAATTCCTAGCTTCGAGCTTAAGAAATTTTGACGAGTGGTAT	1518
Db	48733	GCTGTATTAGTTCACAGAGATAATTCCTAGCTTCGAGCTTAAGAAATTTTGACGAGTGGTAT	48792
QY	1519	GTTTGGGAGACTGCTGAGTCAACCAATAGTTTGTGATGGCAGGAGTTGGAAGTGTGTG	1578
Db	48793	GTTTGGGAGACTGCTGAGTCAACCAATAGTTTGTGATGGCAGGAGTTGGAAGTGTGTG	48852
QY	1579	ATCTGTGGGCACATTTAGCCTATGTGCATGACAGCAATCTAAGTAATGATGTCTTTGAATCA	1638
Db	48853	ATCTGTGGGCACATTTAGCCTATGTGCATGACAGCAATCTAAGTAATGATGTCTTTGAATCA	48912
QY	1639	CAGTATACGCTCCATCGCTGTCACTCAGCTGGATCTCCATCTCTCAGGCTTCTGCTGCCA	1698
Db	48913	CAGTATACGCTCCATCGCTGTCACTCAGCTGGATCTCCATCTCTCAGGCTTCTGCTGCCA	48972
QY	1699	AAAGCCTTTTGTGTTTGTGTTATGATGATGAGTCAAGCTGTTTAAATCAATTCAGT	1758
Db	48973	AAAGCCTTTTGTGTTTGTGTTATGATGATGAGTCAAGCTGTTTAAATCAATTCAGT	49032
QY	1759	GTTTCAGTCTTCGAGATGCTTGATGCTCATATGTTCCCTAAATTTGCCAGTGGGAA	1818
Db	49033	GTTTCAGTCTTCGAGATGCTTGATGCTCATATGTTCCCTAAATTTGCCAGTGGGAA	49092
QY	1819	CTCCTAAATCAAATTTGGCTTCTTAATCAAAGCTTTTAAACCCCTATTTGTTAAAGATGGAAG	1878
Db	49093	CTCCTAAATCAAATTTGGCTTCTTAATCAAAGCTTTTAAACCCCTATTTGTTAAAGATGGAAG	49152
QY	1879	GTGGAGAACTCCCTGAAGTAGCAAGAAAGACTTTCCTCTAGTCGAGCCAAAGTTAAGAAATG	1938
Db	49153	GTGGAGAACTCCCTGAAGTAGCAAGAAAGACTTTCCTCTAGTCGAGCCAAAGTTAAGAAATG	49212
QY	1939	TTCTTATGTTGCCAGTGTGTTTCTGATCTGATGCAAGCAAGAAACACTGGGCTTCTAGA	1998
Db	49213	TTCTTATGTTGCCAGTGTGTTTCTGATCTGATGCAAGCAAGAAACACTGGGCTTCTAGA	49272
QY	1999	ACCAGGCAACTTTGGGAACTTAGACTCCCAAGCTGGACTATGGCTCTACTTTTCAGGCCACAT	2058
Db	49273	ACCAGGCAACTTTGGGAACTTAGACTCCCAAGCTGGACTATGGCTCTACTTTTCAGGCCACAT	49332
QY	2059	GGCTAAAGAGGTTTCAGAAAAAGGTTGGGACAGAGCAACTTTTCACCTTCATATATTT	2118
Db	49333	GGCTAAAGAGGTTTCAGAAAAAGGTTGGGACAGAGCAACTTTTCACCTTCATATATTT	49392
QY	2119	GTATGATCCCTAATGAATGCATAAAATGTTTAAGTTGATGGTATGAATGTAAATFACTGTT	2178
Db	49393	GTATGATCCCTAATGAATGCATAAAATGTTTAAGTTGATGGTATGAATGTAAATFACTGTT	49452

[illegible]

The present invention describes a new composition comprising an antisense oligonucleotide (ON) with low adenosine (up to 15%), which targets nucleic acids involved in bronchoconstriction, allergies, and/or inflammation. The ON can have antiinflammatory, antiallergic, antiasthmatic, cytostatic and analgesic activities. The compositions are useful for the treatment of diseases associated with inflammation, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject. They can be used for treating e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukaemias, lymphomas, carcinomas, and cancers which may metastasize to the lungs, including breast and prostate cancer. The reduction of the adenosine content of the ONs reduces side effects. The A-containing ONs break down with the release of deoxyadenosine which activates adenosine receptors causing bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the nucleotide sequences given in the sequence listing from the present invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185 sequences are also called SEQ ID NO:1 to 185, but the sequences differ from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to AAA33992) are specifically claimed. ONs from the present invention. N.B. Sequences given in the disclosure of the present invention do not match up with their corresponding SEQ ID NO: sequences given in the sequence listing.

.....

CC
CC
CC

pneumonia; pulmonary diseases

New antisense oligonucleotides useful for treating e.g. pulmonary vasoconstriction, inflammation, allergies, asthma, hypertension, bronchitis, emphysema, respiratory distress syndrome, ischemia or cancers -

Disclosure: Page 1106-1138; 1343pp; English.

The present invention describes a new composition comprising an antisense oligonucleotide (ON) with low adenosine (up to 15%), which targets nucleic acids involved in bronchoconstriction, allergies, and/or inflammation. The ON can have antiinflammatory, antiallergic, antiasthmatic, cytostatic and analgesic activities. The compositions are useful for the treatment of diseases associated with inflammation, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject. They can be used for treating e.g. ischemic conditions, pulmonary vasoconstriction, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukemias/lymphomas.

carcinomas, and cancers which may metastasize to the lungs, including breast and prostate cancer. The reduction of the adenosine content of the ONS reduces side effects. The A-containing ONS break down with the release of deoxyadenosine which activates adenosine receptors causing bronchoconstriction and inflammation. AAA33213 to AAA33512 represent the nucleotide sequences given in the sequence listing from the present invention, which correspond to SEQ ID NO:1 to 185, and then the last 185 sequences are also called SEQ ID NO:1 to 185, but the sequences differ from the previously named sequences. SEQ ID NO:11 to 1680 (AAA33223 to AAA33992) are specifically claimed ONS from the present invention. N.B. Sequences given in the disclosure of the present invention do not match up with their corresponding SEQ ID NO: sequences given in the sequence listing.

Sequence 143068 BP; 41194 A; 30126 C; 32402 G; 39346 T; 0 other;

Query Match 56.0%; Score 1250.8; DB 21; Length 143068;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 1252; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 979 AGCCCTTTTACATAGCTCTGGCTGTAGGATTGCCACTCCAAAACACAGTGTGGA 1038
DB 48253 AGCCCTTTTACATAGCTCTGGCTGTAGGATTGCCACTCCAAAACACAGTGTGGA 48312
QY 1039 GGTCCAGAGTGAGACCGAAGAATGTGAAGTCACTACACAGGACTCCTCGATGTT 1098
DB 48313 GGTCCAGAGTGAGACCGAAGAATGTGAAGTCACTACACAGGACTCCTCGATGTT 48372
QY 1099 CGTGGAAAAGGAAGTCAATTTGGCAGAGCCCTTGAAGCAGTCTTCAGGACAAAGGA 1158
DB 48373 CGTGGAAAAGGAAGTCAATTTGGCAGAGCCCTTGAAGCAGTCTTCAGGACAAAGGA 48432
QY 1159 GCTAGAGACAGAAATGACAGATCTCTGCTTTGGAATACAGCTCGCTTCACAGATG 1218
DB 48433 GCTAGAGACAGAAATGACAGATCTCTGCTTTGGAATACAGCTCGCTTCACAGATG 48492
QY 1219 TGTGATTCAGTGAATCTTGGTGTCTACGTTACAGCAGGAGGCTGAGAGGAGAG 1278
DB 48493 TGTGATTCAGTGAATCTTGGTGTCTACGTTACAGCAGGAGGCTGAGAGGAGAG 48552
QY 1279 AGACTCAGCTGGTGTGAAACAGTATTTCCAAACTACCTCCAGTTCCTCATTTTG 1338
DB 48553 AGACTCAGCTGGTGTGAAACAGTATTTCCAAACTACCTCCAGTTCCTCATTTTG 48612
QY 1339 AATACAGGATAGAGTTCAGACTTTTAAATAGTAAATAAATTAAGCTGAAAC 1398
DB 48613 AATACAGGATAGAGTTCAGACTTTTAAATAGTAAATAAATTAAGCTGAAAC 48672
QY 1399 TGAACCTTGTAAATGTGTAAGAGTGTAGTTTGTGCTATCATGTCAACCTGAAAT 1458
DB 48673 TGAACCTTGTAAATGTGTAAGAGTGTAGTTTGTGCTATCATGTCAACCTGAAAT 48732
QY 1459 GCTGTATTAGTACAGAGATAATTTAGCTTTGAGCTTAGAATTTTTCAGCAGTGTAT 1518
DB 48733 GCTGTATTAGTACAGAGATAATTTAGCTTTGAGCTTAGAATTTTTCAGCAGTGTAT 48792
QY 1519 GTTTGGAGACTGCTGAGTCAACCAATAGTTTGTGTTGAGTGGCAGAGTGTGAAGTGTG 1578
DB 48793 GTTTGGAGACTGCTGAGTCAACCAATAGTTTGTGTTGAGTGGCAGAGTGTGAAGTGTG 48852
QY 1579 ATCTGTGGGACATAGCTATGTGATGAGTCAATCAATCAATCAATCAATCAATCA 1638
DB 48853 ATCTGTGGGACATAGCTATGTGATGAGTCAATCAATCAATCAATCAATCAATCA 48912
QY 1639 CAGTATAGCTTCATCGCTGTCATCTCAGTGGATCTCCATCTCTCAGGCTTCTGCGCA 1698
DB 48913 CAGTATAGCTTCATCGCTGTCATCTCAGTGGATCTCCATCTCTCAGGCTTCTGCGCA 48972
QY 1699 AAGCCCTTTGTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 1758
DB 48973 AAGCCCTTTGTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 49032
QY 1759 GTTTCAGTGTCTGCGAGATGCTTGTGATGCTATATGTTCCCTAATTTGCGAGTGGAA 1818

DB 49033 GTTTCAGTGTCTGCGAGATGCTTGTGATGCTCATATGTTTCCCTATTTTCCAGTGGAA 49092
QY 1819 CTCCTAAATCAAAATTTGGCTTCTTAATCAAAAGCTTTTAAACCCCTATTGGTAAAGTGAAG 1878
DB 49093 CTCCTAAATCAAAATTTGGCTTCTTAATCAAAAGCTTTTAAACCCCTATTGGTAAAGTGAAG 49152
QY 1879 GTGAGAGAGCTCCCTGAAGTAAAGCAAGTTCCTCTTAGTCGAGCCAAAGTTAAAGATG 1938
DB 49153 GTGAGAGAGCTCCCTGAAGTAAAGCAAGTTCCTCTTAGTCGAGCCAAAGTTAAAGATG 49212
QY 1939 TTTCTATGTTGCCAGTGTGTTTCTGATGATGCAAGCAAGCAACACTGGGCTTCTAGA 1998
DB 49213 TTTCTATGTTGCCAGTGTGTTTCTGATGATGCAAGCAAGCAACACTGGGCTTCTAGA 49272
QY 1999 ACCAGCAACTTTGGGAACTAGACTCCCAAGCTGGACTATGGCTCTACTTTTCAGGCCACAT 2058
DB 49273 ACCAGCAACTTTGGGAACTAGACTCCCAAGCTGGACTATGGCTCTACTTTTCAGGCCACAT 49332
QY 2059 GGTAAAGAAAGTTCAGAAAAGTGGGACAGAGCAGAACTTTCCCTTCATATATTT 2118
DB 49333 GGTAAAGAAAGTTCAGAAAAGTGGGACAGAGCAGAACTTTCCCTTCATATATTT 49392
QY 2119 GTATGATCCTTAATGAATGCAATAAATGTTAAGTGTGATGATGCAATGTAATGTAATGTT 2178
DB 49393 GTATGATCCTTAATGAATGCAATAAATGTTAAGTGTGATGATGCAATGTAATGTAATGTT 49452
QY 2179 TTTTAAACATCTATGTTGGAAAATAAATCAATGCTATAACTATGTTGATATAAAG 2232
DB 49453 TTTTAAACATCTATGTTGGAAAATAAATCAATGCTATAACTATGTTGATATAAAG 49506

RESULT 6
ABL68124
ID ABL68124 standard; DNA; 143068 BP.
XX ABL68124;
XX AC
XX XX
DT 15-MAY-2002 (first entry)
XX Ovary cancer related gene sequence SEQ ID NO:6461.
DE Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;
XX stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;
KW cytostatic; gene therapy; antineoplastic; Wilms' tumour; adenocarcinoma;
KW gene; ds.
XX Homo sapiens.
OS WO200194629-A2.
XX PN
XX PD 13-DEC-2001.
XX 30-MAY-2001; 2001WO-US10838.
PF 05-JUN-2000; 2000US-209473P.
XX 05-JUN-2000; 2000US-209531P.
PR 18-SEP-2000; 2000US-233133P.
PR 18-SEP-2000; 2000US-233617P.
PR 20-SEP-2000; 2000US-234009P.
PR 20-SEP-2000; 2000US-234034P.
PR 20-SEP-2000; 2000US-234052P.
PR 22-SEP-2000; 2000US-234509P.
PR 22-SEP-2000; 2000US-234567P.
PR 25-SEP-2000; 2000US-234923P.
PR 25-SEP-2000; 2000US-234924P.
PR 25-SEP-2000; 2000US-235077P.
PR 25-SEP-2000; 2000US-235082P.
PR 25-SEP-2000; 2000US-235134P.
PR 25-SEP-2000; 2000US-235280P.
PR 26-SEP-2000; 2000US-235637P.
PR 26-SEP-2000; 2000US-235638P.
PR 27-SEP-2000; 2000US-235711P.

RESULT 7
 AAA35151
 ID AAA35151 standard; DNA; 149412 BP.
 XX
 AC AAA35151;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Human adenosine receptor related polynucleotide 2nd SEQ ID NO:25.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antinflammatory;
 KW antiallergic; antiallergic; cytotatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 WO200009525-A2.
 XX
 PD 24-FEB-2000.
 XX
 PF 03-AUG-1999; 99WO-US17712.
 XX
 PR 03-AUG-1998; 98US-0095212.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 NYce JW;
 XX
 WPI; 2000-205971/18.
 XX
 New antisense oligonucleotides useful for treating e.g. pulmonary
 vasoconstriction, inflammation, allergies, asthma, hypertension,
 bronchitis, emphysema, respiratory distress syndrome, ischemia or
 cancers -
 XX
 Disclosure; Page 1138-1171; 1343pp; English.
 XX
 The present invention describes a new composition comprising an
 antisense oligonucleotide (ON) with low adenosine (up to 15%), which
 targets nucleic acids involved in bronchoconstriction, allergies, and/or
 inflammation. The ON can have antinflammatory, antiallergic,
 antiallergic, cytotatic and analgesic activities. The compositions are
 useful for the treatment of diseases associated with inflammation,
 impaired airways, including lung disease and diseases whose secondary
 effects afflict the lungs of a subject. They can be used for treating
 e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, cystic
 asthma, impaired respiration, respiratory distress syndrome, pain, chronic
 fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 carcinomas, and cancers which may metastasize to the lungs, including
 breast and prostate cancer. The reduction of the adenosine content of
 the ONs reduces side effects. The A-containing ONs break down with the
 release of deoxyadenosine which activates adenosine receptors causing
 bronchoconstriction and inflammation. AAA35151 to AAA35312 represent the
 nucleotide sequences given in the sequence listing from the present
 invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 differ from the previously named sequences. SEQ ID NO:11 to 1680
 (AAA32323 to AAA33992) are specifically claimed ONs from the present
 invention. N.B. Sequences given in the disclosure of the present
 invention do not match up with their corresponding SEQ ID NO: sequences
 given in the sequence listing.

Sequence 149412 BP; 43049 A; 31388 C; 33852 G; 41123 T; 0 other;

Query Match 56.0%; Score 1250.8; DB 21; Length 149412;
 Best Local Similarity 99.8%; Pred. No. 0;

	Matches	1252;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	979	AGCCTTTTTCACATAGCTCTTGGCTGTAGGATTGCCCACTCCAAAACACAGTGTGGGA	1038							
DB	54597	AGCCTTTTTCACATAGCTCTTGGCTGTAGGATTGCCCACTCCAAAACACAGTGTGGGA	54656							
QY	1039	GGTCCAGGAGTGAGACAGGAAAGTGTGAAAGTGTGAAAGTGTGAAAGTGTGAAAGTGTG	1098							
DB	54657	GGTCCAGGAGTGAGACAGGAAAGTGTGAAAGTGTGAAAGTGTGAAAGTGTGAAAGTGTG	54716							
QY	1099	CGTGGAAAAGAAAGTCAATTTGGCAGAGCCCTGAAAGCCAGTCTTTCAGGACAAAGAGGA	1158							
DB	54717	CGTGGAAAAGAAAGTCAATTTGGCAGAGCCCTGAAAGCCAGTCTTTCAGGACAAAGAGGA	54776							
QY	1159	GCTTAGAGACAGAAATGACAGATCTCTGCTTTGGAATTCACACGCTTGGCTTTCACAGATG	1218							
DB	54777	GCTTAGAGACAGAAATGACAGATCTCTGCTTTGGAATTCACACGCTTGGCTTTCACAGATG	54836							
QY	1219	TGTGATTTCACAGTGTGAAATCTTGGTGTCTAGCTTACCAGGAGGAGGCTGAGAGGAGAG	1278							
DB	54837	TGTGATTTCACAGTGTGAAATCTTGGTGTCTAGCTTACCAGGAGGAGGCTGAGAGGAGAG	54896							
QY	1279	AGACTCCAGCTGGGTTGGAAAACAGATATTTTCCAACTACCTTCCAGTTCCTCATTTTGG	1338							
DB	54897	AGACTCCAGCTGGGTTGGAAAACAGATATTTTCCAACTACCTTCCAGTTCCTCATTTTGG	54956							
QY	1339	AATACAGGCATAGAGTTTCAGACTTTTAAATAGTAAATAAAATTAAGTCTGCTGCTGCTG	1398							
DB	54957	AATACAGGCATAGAGTTTCAGACTTTTAAATAGTAAATAAAATTAAGTCTGCTGCTGCTG	55016							
QY	1399	TGCAACTTGTAAATGTGTAAGAGTATAGTTTGTAGTCTATCATGTCAAACTGCTGCTGCTG	1458							
DB	55017	TGCAACTTGTAAATGTGTAAGAGTATAGTTTGTAGTCTATCATGTCAAACTGCTGCTGCTG	55076							
QY	1459	GCTGTATTAGTCACAGATATATCTAGCTTTAGCTTAAAGATTTTTCAGGAGGCTGCTGCTG	1518							
DB	55077	GCTGTATTAGTCACAGATATATCTAGCTTTAGCTTAAAGATTTTTCAGGAGGCTGCTGCTG	55136							
QY	1519	GTTTGGGAGACTGCTGAGTCAACCAATAGTTTGTGATTGGCAGGAGTGGAAAGTGTGTG	1578							
DB	55137	GTTTGGGAGACTGCTGAGTCAACCAATAGTTTGTGATTGGCAGGAGTGGAAAGTGTGTG	55196							
QY	1579	ATCTGTGGGACATAGGCTATGTGCATGCAGCATCTAAGTAAATGCTGCTGCTGCTGCTGCTG	1638							
DB	55197	ATCTGTGGGACATAGGCTATGTGCATGCAGCATCTAAGTAAATGCTGCTGCTGCTGCTGCTG	55256							
QY	1639	CAGTATACGCTCCATCGCTGCTCATCTCAGCTGGAATCTCCATTTCTCTCAGGCTTGTGCTCA	1698							
DB	55257	CAGTATACGCTCCATCGCTGCTCATCTCAGCTGGAATCTCCATTTCTCTCAGGCTTGTGCTCA	55316							
QY	1699	AAAGCCTTTTGTGTTTGTGTTTGTATCATATGAAAGTCAAGCTTGTGTTTAAATGCTGCTG	1758							
DB	55317	AAAGCCTTTTGTGTTTGTGTTTGTATCATATGAAAGTCAAGCTTGTGTTTAAATGCTGCTG	55376							
QY	1759	GTTTTCAGTGTGCGAGATGCTCTGCTGCTCATATGTTTCCCTAATTTTCCAGTGGGAA	1818							
DB	55377	GTTTTCAGTGTGCGAGATGCTCTGCTGCTCATATGTTTCCCTAATTTTCCAGTGGGAA	55436							
QY	1819	CTCCTAAATCAAAATGGGCTTCTTAATCAAAAGCTTTTAAACCCCTATTGGTAAAGAAATGAAG	1878							
DB	55437	CTCCTAAATCAAAATGGGCTTCTTAATCAAAAGCTTTTAAACCCCTATTGGTAAAGAAATGAAG	55496							
QY	1879	GTGGAGAAGCTCCCTGAAAGTAAAGAAAGTCTTCTCTTCTAGTCGAGCCCAAGTTAAGAAATG	1938							
DB	55497	GTGGAGAAGCTCCCTGAAAGTAAAGAAAGTCTTCTCTTCTAGTCGAGCCCAAGTTAAGAAATG	55556							
QY	1939	TTCCTTATGTTGCCAGTGTGTTTCTGATCTGATGCAAGCAAGAAACACTGGGCTTCTAGA	1998							
DB	55557	TTCCTTATGTTGCCAGTGTGTTTCTGATCTGATGCAAGCAAGAAACACTGGGCTTCTAGA	55616							
QY	1999	ACCAGCAACTTGGGAACTAGACTCCCAAGCTGAGTATGGCTCTACTTTTCAGGCCACAT	2058							
DB	55617	ACCAGCAACTTGGGAACTAGACTCCCAAGCTGAGTATGGCTCTACTTTTCAGGCCACAT	55676							

QY 2059 GGCTAAAGAGGTTTCAGAAAGAGTGGGACAGAGCAGAACTTTCACCTTCATATATTT 2118
 Db 55677 GGCTAAAGAGGTTTCAGAAAGAGTGGGACAGAGCAGAACTTTCACCTTCATATATTT 55736
 QY 2119 GTATGATCCTTAATGAATGCATATAAATGTAAGTTGATGGTGATGAATGTAATACTGTT 2178
 Db 55737 GTATGATCCTTAATGAATGCATATAAATGTAAGTTGATGGTGATGAATGTAATACTGTT 55796
 QY 2179 TTTAACTATGATTTGGAAATATAATCAATGCTATTAACATGTTGATATAAAG 2232
 Db 55797 TTTAACTATGATTTGGAAATATAATCAATGCTATTAACATGTTGATATAAAG 55850

RESULT 8

AAF21273
 ID AAF21273 standard; DNA; 152740 BP.

XX AC AAF21273;

XX AC AAF21273;

DT 14-MAR-2001 (first entry)

XX DT 14-MAR-2001 (first entry)

DE Human low adenosine antisense oligonucleotide related sequence #2840.

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.

XX Homo sapiens.

OS Wo200062736-A2.

PN 26-OCT-2000.

XX 24-MAR-2000; 2000WO-US08020.

XX 06-APR-1999; 98US-0127958.

PR (UYBC-) UNIV EAST CAROLINA.

XX (NYCE/) NYCE J W.

PI Nyce JW;

XX WPI; 2000-679539/66.

XX Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -

XX Disclosure; Page 1219-1254; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (1) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (1) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (1) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide

CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention.

XX Sequence 152740 BP; 44169 A; 32023 C; 34549 G; 41999 T; 0 other;
 SQ

Query Match 56.0%; Score 1250.8; DB 21; Length 152740;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 1252; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 979 AGCCCTTTTTCACATAGCTCTTGCTGTAGGATTGCCCTCCCAAAACAGTGTGTGA 1038
 Db 54597 AGCCCTTTTTCACATAGCTCTTGCTGTAGGATTGCCCTCCCAAAACAGTGTGTGA 54656
 QY 1039 GGTCCAGGAGTGAGCAGCAGGAAAGATGTGAAGTGAATGCTCCTCGATGGT 1098
 Db 54657 GGTCCAGGAGTGAGCAGCAGGAAAGATGTGAAGTGAATGCTCCTCGATGGT 54716
 QY 1099 CGTGGAAAGGAAAGTCAATTTGGCAGAGCCCTGAGCCAGTCTTCCAGGACAAAGAGGA 1158
 Db 54717 CGTGGAAAGGAAAGTCAATTTGGCAGAGCCCTGAGCCAGTCTTCCAGGACAAAGAGGA 54776
 QY 1159 GCCTAGACACAGAAATGACAGATCTCTGCTTTGGAAATCACACGCTCTGCAGATG 1218
 Db 54777 GCCTAGACACAGAAATGACAGATCTCTGCTTTGGAAATCACACGCTCTGCAGATG 54836
 QY 1219 TGTGATTCACAGTGTGAATCTTGGTGTCTACGTTACCGCAGGAGGCTGAGAGGAG 1278
 Db 54837 TGTGATTCACAGTGTGAATCTTGGTGTCTACGTTACCGCAGGAGGCTGAGAGGAG 54896
 QY 1279 AGACTCCAGCTGGGTTGGAAACACAGTATTTTCCAACTACCTTCCAGTCTCTCATTTTG 1338
 Db 54897 AGACTCCAGCTGGGTTGGAAACACAGTATTTTCCAACTACCTTCCAGTCTCTCATTTTG 54956
 QY 1339 AATACAGGCATAGAGTTCAGAGCTTTTAAATAGTAAATAAATAAAGCTGAAAC 1398
 Db 54957 AATACAGGCATAGAGTTCAGAGCTTTTAAATAGTAAATAAATAAAGCTGAAAC 55016
 QY 1399 TGCAACTTGTAAATGTGTAAGAGTATAGTTTGGTGTGCTATCATGTCAAAAGTGAAT 1458
 Db 55017 TGCAACTTGTAAATGTGTAAGAGTATAGTTTGGTGTGCTATCATGTCAAAAGTGAAT 55076
 QY 1459 GCTGTATTAGTCACAGAGATAATCTAGCTTTGAGCTTAAAGAAATTTGAGCAGGTTGAT 1518
 Db 55077 GCTGTATTAGTCACAGAGATAATCTAGCTTTGAGCTTAAAGAAATTTGAGCAGGTTGAT 55136
 QY 1519 GTTTGGGAGACTGCTGAGTCAACCAATAGTTTGGTGTGCTGAGGAGTGGAGTGTG 1578
 Db 55137 GTTTGGGAGACTGCTGAGTCAACCAATAGTTTGGTGTGCTGAGGAGTGGAGTGTG 55196
 QY 1579 ATCTGTGGGACATTAAGCTTATGTCATGTCAGCATCTCAATGATCTCGTTGAATCA 1638
 Db 55197 ATCTGTGGGACATTAAGCTTATGTCATGTCAGCATCTCAATGATCTCGTTGAATCA 55256
 QY 1639 CAGTATACGCTCCATCCCTCTCATCTCAGCTGGATCTCAATCTCTCAGGCTTGCTGCA 1698
 Db 55257 CAGTATACGCTCCATCCCTCTCATCTCAGCTGGATCTCAATCTCTCAGGCTTGCTGCA 55316
 QY 1699 AAAGCCTTTTGTGTTTGTGTTTGTATCATTTAAGTCAATGATGATGATGATGATGAT 1758
 Db 55317 AAAGCCTTTTGTGTTTGTGTTTGTATCATTTAAGTCAATGATGATGATGATGATGAT 55376

CC	family, degenerate oligo primers were designed corresp. to the conserved sequences R7167 in the second and R79168 in the third transmembrane domains of the MIP-1alpha/RANTES receptor, the IL-8 receptors and the HUMSTRS orphan receptor (GenBank Accession #M92933. The degenerate oligo incorporating EcoRI and XhoI sites at their 5' ends are Q96299 and Q96300. Amplification of cDNA derived from MM6 cells with the primers yielded a number of PCR products. One cDNA appeared to encode a novel protein. To obtain a full-length version of this clone, a MM6 cDNA library was constructed in pPROG and probed with the PCR product. A 2.1 kb cDNA clone was obtained. Analysis of additional clones in the MM6 cDNA library revealed a second sequence that was identical to the 2.1 kb cDNA sequence first obtained from the 5' UTR through the putative seventh transmembrane domain but contained a different cytoplasmic tail. The second sequence appears to represent alternative splicing of the carboxyl-terminal tail of the MCP-1R protein. The two sequences are denoted MCP-1RA and MCP-1RB (see Q96297/R79165 & Q96298/R79166). Active mature MCP-1RA has a predicted mol. wt. of about 42,000 daltons. MCP-1RB has a mol. wt. of about 41,000 daltons.	CC
CC	Sequence 1979 BP; 530 A; 434 C; 452 G; 563 T; 0 other;	CC
XX	Query Match 43.9%; Score 980; DB 16; Length 1979;	CC
XX	Best Local Similarity 100.0%; Pred. No. 9,8e-263;	CC
XX	Matches 980; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	CC
QY	1 GGATTGAACAAGGACGATTTCCCAAGTATATCCCAACATGCTGCCACATCTGTTCT 60	QY
DB	42 GGATTGAACAAGGACGATTTCCCAAGTATATCCCAACATGCTGCCACATCTGTTCT 101	DB
QY	61 CGGTTTATCAGAATAACCAACGAGAGCGGTGAAGAAGTACACACCTTTTGTGATTATGAT 120	QY
DB	102 CGGTTTATCAGAATAACCAACGAGAGCGGTGAAGAAGTACACACCTTTTGTGATTATGAT 161	DB
QY	121 TACGGTCTCCCTGTCATATAATTTGACGTGAAGCAAAATTTGGGCCCCAACCTCTGCCCTCCG 180	QY
DB	162 TACGGTCTCCCTGTCATATAATTTGACGTGAAGCAAAATTTGGGCCCCAACCTCTGCCCTCCG 221	DB
QY	181 CTCTACTCGCTGGTGTTCATCTTTGGTTTGTGGGCAACATGCTGGTGGTCTCTATCTTA 240	QY
DB	222 CTCTACTCGCTGGTGTTCATCTTTGGTTTGTGGGCAACATGCTGGTGGTCTCTATCTTA 281	DB
QY	241 ATAACTGCAAAAAGCTGAAGTGTCTGACATGACATTTACCTGCTCAACCTGCCATCTCT 300	QY
DB	282 ATAACTGCAAAAAGCTGAAGTGTCTGACATGACATTTACCTGCTCAACCTGCCATCTCT 341	DB
QY	301 GATCTGCTTTTCTTATTACTCTCCCATTTGGGCTCACCTGCTGCTCAAAATGAGTGGGTC 360	QY
DB	342 GATCTGCTTTTCTTATTACTCTCCCATTTGGGCTCACCTGCTGCTCAAAATGAGTGGGTC 401	DB
QY	361 TTTGGGAATGCAATGTGCAAAATTTACAGGGGTGTATCATCGGTATTATTGGCGGA 420	QY
DB	402 TTTGGGAATGCAATGTGCAAAATTTACAGGGGTGTATCATCGGTATTATTGGCGGA 461	DB
QY	421 ATCTTCTTCATCATCTCCCTCCAGGAATCATCTTTACTAATGCCAGAAAGAGATTCTGTT 480	QY
DB	462 ATCTTCTTCATCATCTCCCTCCAGGAATCATCTTTACTAATGCCAGAAAGAGATTCTGTT 521	DB
QY	481 GCTTTAAAAGCCAGGAGCGGTCACTTTGGGGTGGTGAACAAGTGTATCACCTGGTGGTG 540	QY
DB	522 GCTTTAAAAGCCAGGAGCGGTCACTTTGGGGTGGTGAACAAGTGTATCACCTGGTGGTG 581	DB
QY	541 GCTGTGTTTGTCTGTGCCAGGAATCATCTTTACTAATGCCAGAAAGAGATTCTGTT 600	QY
DB	582 GCTGTGTTTGTCTGTGCCAGGAATCATCTTTACTAATGCCAGAAAGAGATTCTGTT 641	DB
QY	601 TATGCTCTGCGCCCTTATTTTCCAGGAGATGGAATAATTTCCACACAATATAGGAAAC 660	QY
DB	642 TATGCTCTGCGCCCTTATTTTCCAGGAGATGGAATAATTTCCACACAATATAGGAAAC 701	DB
QY	661 ATTTTGGGGCTGGTCTCCCGCTGCTCATCATGTTGTCATCTGCTACTCGGGAATCTGAAA 720	QY
DB	702 ATTTTGGGGCTGGTCTCCCGCTGCTCATCATGTTGTCATCTGCTACTCGGGAATCTGAAA 761	DB

AAQ96298 standard; cDNA; 1979 BP.

AAQ96298; 29-DEC-1995 (first entry)

Human monocyte chemoattractant protein-1 receptor MCP-1RB.

Monocyte chemoattractant protein-1 receptor; MCP-1R; chemokine; ss.

Homo sapiens.

Key 81..1160

Location/Qualifiers

/*tag= a

W09519436-A.

20-JUL-1995.

11-JAN-1995; 95WO-US00476.

13-JAN-1994; 94US-0182962.

(REGC) UNIV CALIFORNIA.

Charo I, Coughlin S;

WPI; 1995-263866/34.

P-PSDB; AAR79166.

DNA encoding monocyte chemo-attractant protein-1 receptor - used partic. for identifying antagonists and for treating diseases characterised by monocyte infiltrates

Disclosure; Fig 2; 84pp; English.

To identify and clone new members of the chemokine receptor gene

XX
sequence 1083 BP. 256 A: 260 C: 246 G: 321 T: 0 other:

XX	Human immune system associated gene SEQ ID NO: 308.
XX	Human; immune system disease; cytosine methylation; antiasthmatic;
XX	antiartherosclerotic; antianemic; cytosine; cytosine; cytosine;
KW	neuroprotective; anti-HIV; anticonvulsant; ophthalmologic;
KW	antirheumatic; antithyroid; antidiabetic; antipsoriatic;
KW	antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW	acute myeloid leukemia; Alzheimer's disease; AIDS; epilepsy;
KW	neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW	gene; ds.
OS	Homo sapiens.
XX	WO200200928-A2.
PN	03-JAN-2002.
XX	02-JUL-2001; 2001WO-EP07537.
XX	30-JUN-2000; 2000DE-1032529.
PR	01-SEP-2000; 2000DE-1043826.
PR	(EPIG-) EPIGENOMICS AG.
XX	Olek A, Piepenbrock C, Berlin K;
PI	WPI; 2002-130909/17.
XX	Nucleic acid comprising fragment of chemically modified gene, useful
PT	for diagnosis and treatment of diseases associated with abnormal
PT	cytosine methylation -
XX	Claim 1; SEQ ID NO 308; 32pp + Sequence Listing; German.
PS	The present invention provides a number of human immune system associated
XX	genes which are modified by the methylation of cytosines. The sequences
CC	can be used in the diagnosis and treatment of immune system disorders,
CC	including eye diseases such as retinopathy, neovascular glaucoma and
CC	macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC	leukemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC	rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC	diseases. The present sequence is a gene of the invention.
XX	Sequence 10528 BP; 2873 A; 86 C; 2164 G; 5405 T; 0 other;
SQ	
Query Match 29.9%; Score 668.2; DB 24; Length 10528;	
Best Local Similarity 80.2%; Pred. No. 2.6e-175;	
Matches 784; Conservative 0; Mismatches 193; Indels 0; Gaps 0	
QY	3 ATTGAACAAGGAGCGATTTCCTCCAGTACATCCACACATGCTCCACATCTCGTCTCG 62
Db	
2187	ATTAAACAAAAGCGATTTCCTCCAAATACATCCACACATACATCCACATCTCGTCTCG 2128
QY	63 GTTATCAGAAATACCAAGAGCGGTGGAAGATCACCACCTTTTGTGATTATGATTA 122
Db	
2127	ATTATCAAAATACCAAGAAACGATAAAAAATCACCACCTTTTAAATATAATTA 2068
QY	123 CGGTGCTCCCTGTCATAAATTGACGTGAAGCAATTTGGGGCCCACTCCTCCCTCCGCT 182
Db	
2067	CGATACTCCCTATCATATAAATTAAACGTAACCAAAATTAACCACTCCTACCTCCGCT 2008
QY	183 CTACTCGCTGGTCTTCATCTTTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 242
Db	
2007	CTACTCGCTAAATTCATCTTTAAATTTTAAACACATACATTAATCGTCTCATCTTAAT 1948
QY	243 AAACCTCAAAAAGCTGAAGTGTGACTGACATTTTACCTGCTCAACCTGCCCACTCTCTGA 302
Db	
1947	AAACTCAAAAAGCTGAAGTGTGACTGACATTTTACCTGCTCAACCTGCCCACTCTCTAA 1888
QY	303 TCTGCTTTTCTTATTACTCTCCATTTGGGCTCACTCTGCTGCAAAATGAGTGGGCTCT 362
Db	
1887	TCTACTTTTCTTATTACTCTCCATTTAAACACTCACTTACTACTCAAAATTAATTAATCTT 1828

601 TAAGCTGTGGCCCTATTATTCACGAGATGGAATAATTTCCACACAATAATCAGGGAAC 660
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
8940 TATGTTTGCGTTTTTATTTTTTACGAGGATGGAATAATTTTATATAATAATCAGGGAAT 8999

Dbb

PF 02-JUL-2001; 2001WO-EP07537.
XX

Dib

Search completed: June 1, 2003, 16:03:45
Job time : 1968.44 secs

